Multi-parameter systematic strategies for predictive, preventive and personalised medicine in cancer

EPMA Journal

Volumn 4, Issue 1, 2013, Pages

  Hu, Rong ^a   Wang, Xiaowei ^a   Zhan, Xianquan ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Genomics; Metabolomics; Multi parameter systematic strategy; Predictive, preventive and personalised medicine; Proteomics; Systems biology; Transcriptomics

Indexed keywords

DACTOLISIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN; PERTUZUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; VOXTALISIB; [1 (4 OXO 8 PHENYL 4H 1 BENZOPYRAN 2 YL)MORPHOLINIO]METHOXYSUCCINYLARGINYLGLYCYLASPARTYLSERINE ACETATE;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RESISTANCE; CARCINOGENESIS; GENOMICS; HUMAN; MEDICINE; METABOLOMICS; MOLECULARLY TARGETED THERAPY; NEOPLASM; PARAMETRIC TEST; PERSONALIZED MEDICINE; PREVENTIVE MEDICINE; PRIORITY JOURNAL; PROTEOMICS; REVIEW; SYSTEMS BIOLOGY; TRANSCRIPTOMICS; TUMOR GROWTH;

EID: 84976905617     PISSN: 18785077     EISSN: 18785085     Source Type: Journal    
DOI: 10.1186/1878-5085-4-2     Document Type: Review

References (98)

1. Doll R, Peto R: The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. J Natl Cancer Inst. 1981, 66: 1191-1308.
2. Pollack IF: Multidisciplinary management of childhood brain tumors: a review of outcomes, recent advances, and challenges. Neurosurg Pediatr. 2011, 8: 135-148. 10.3171/2011.5.PEDS1178.
3. Maximo V, Lima J, Prazeres H, Soares P, Sobrinho-Simoes M: The biology and the genetics of Hurthle cell tumors of the thyroid. Endocr Relat Cancer. 2012, 19: R131-R147. 10.1530/ERC-11-0354.
4. Friedl P, Alexander S: Cancer invasion and the microenvironment: plasticity and reciprocity. Cell. 2011, 147: 992-1009. 10.1016/j.cell.2011.11.016.
5. Kang M, Buckley YM, Lowe AJ: Testing the role of genetic factors across multiple independent invasions of the shrub Scotch broom (Cytisus scoparius). Mol Ecol. 2007, 16: 4662-4673. 10.1111/j.1365-294X.2007.03536.x.
6. Jobling MA: The impact of recent events on human genetic diversity. Philos Trans R Soc Lond B Biol Sci. 2012, 367: 793-799. 10.1098/rstb.2011.0297.
7. Chen AY, Chen PM, Chen YJ: DNA topoisomerase I drugs and radiotherapy for lung cancer. J Thorac Dis. 2012, 4: 390-397.
8. McGeer PL, McGeer EG: NSAIDs and Alzheimer disease: epidemiological, animal model and clinical studies. Neurobiol Aging. 2007, 28: 639-647. 10.1016/j.neurobiolaging.2006.03.013.
9. Low YL, Wedren S, Liu J: High-throughput genomic technology in research and clinical management of breast cancer. Evolving landscape of genetic epidemiological studies. Breast Cancer Res. 2006, 8: 209-10.1186/bcr1511.
10. Zhan X, Desiderio DM: The use of variations in proteomes to predict, prevent, and personalize treatment for clinically nonfunctional pituitary adenomas. EPMA J. 2010, 1: 439-459. 10.1007/s13167-010-0028-z.
11. Golubnitschaja O, Costigliola V, EPMA: General report & recommendations in predictive, preventive and personalised medicine 2012: white paper of the European Association for Predictive, Preventive and Personalised Medicine. EPMA J. 2012, 3: 14-10.1186/1878-5085-3-14.
12. Dawson MA, Kouzarides T: Cancer epigenetics: from mechanism to therapy. Cell. 2012, 150: 12-27. 10.1016/j.cell.2012.06.013.
13. Chaffer CL, Weinberg RA: A perspective on cancer cell metastasis. Science. 2011, 331: 1559-1564. 10.1126/science.1203543.
14. Valastyan S, Weinberg RA: Tumor metastasis: molecular insights and evolving paradigms. Cell. 2011, 147: 275-292. 10.1016/j.cell.2011.09.024.
15. Gonzalez-Angulo AM, Iwamoto T, Liu S, Chen H, Do KA, Hortobagyi GN, Mills GB, Meric-Bernstam F, Symmans WF, Pusztai L: Gene expression, molecular class changes, and pathway analysis after neoadjuvant systemic therapy for breast cancer. Clin Cancer Res. 2012, 18: 1109-1119. 10.1158/1078-0432.CCR-11-2762.
16. Nosho K, Baba Y, Tanaka N, Shima K, Hayashi M, Meyerhardt JA, Giovannucci E, Dranoff G, Fuchs CS, Ogino S: Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. J Pathol. 2010, 222: 350-366. 10.1002/path.2774.
17. Zhan X, Desiderio DM: Signaling pathway networks mined from human pituitary adenoma proteomics data. BMC Med Genomics. 2010, 3: 13-10.1186/1755-8794-3-13.
18. Laplante M, Sabatini DM: mTOR signaling in growth control and disease. Cell. 2012, 149: 274-293. 10.1016/j.cell.2012.03.017.
19. Chen J: Multiple signal pathways in obesity-associated cancer. Obes Rev. 2011, 12: 1063-1070. 10.1111/j.1467-789X.2011.00917.x.
20. Janku F, Wheler JJ, Westin SN, Moulder SL, Naing A, Tsimberidou AM, Fu S, Falchook GS, Hong DS, Garrido-Laguna I, Luthra R, Lee JJ, Lu KH, Kurzrock R: PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol. 2012, 30: 777-782. 10.1200/JCO.2011.36.1196.
21. Aziz SA, Jilaveanu LB, Zito C, Camp RL, Rimm DL, Conrad P, Kluger HM: Vertical targeting of the phosphatidylinositol-3 kinase pathway as a strategy for treating melanoma. Clin Cancer Res. 2010, 16: 6029-6039. 10.1158/1078-0432.CCR-10-1490.
22. Bhende PM, Park SI, Lim MS, Dittmer DP, Damania B: The dual PI3K/mTOR inhibitor, NVP-BEZ235, is efficacious against follicular lymphoma. Leukemia. 2010, 24: 1781-1784. 10.1038/leu.2010.154.
23. Chapuis N, Tamburini J, Green AS, Vignon C, Bardet V, Neyret A, Pannetier M, Willems L, Park S, Macone A, Maira SM, Ifrah N, Dreyfus F, Herault O, Lacombe C, Mayeux P, Bouscary D: Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia. Clin Cancer Res. 2010, 16: 5424-5435. 10.1158/1078-0432.CCR-10-1102.
24. Santiskulvong C, Konecny GE, Fekete M, Chen KY, Karam A, Mulholland D, Eng C, Wu H, Song M, Dorigo O: Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma. Clin Cancer Res. 2011, 17: 2373-2384. 10.1158/1078-0432.CCR-10-2289.
25. Prasad G, Sottero T, Yang X, Mueller S, James CD, Weiss WA, Polley MY, Ozawa T, Berger MS, Aftab DT, Prados MD, Haas-Kogan DA: Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide. Neuro Oncol. 2011, 13: 384-392. 10.1093/neuonc/noq193.
26. Garlich JR, De P, Dey N, Su JD, Peng X, Miller A, Murali R, Lu Y, Mills GB, Kundra V, Shu HK, Peng Q, Durden DL: A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity. Cancer Res. 2008, 68: 206-215. 10.1158/0008-5472.CAN-07-0669.
27. Longo DL: Tumor heterogeneity and personalized medicine. N Engl J Med. 2012, 366: 956-957. 10.1056/NEJMe1200656.
28. Moreno CS, Evans CO, Zhan X, Okor M, Desiderio DM, Oyesiku NM: Novel molecular signaling and classification of human clinically nonfunctional pituitary adenomas identified by gene expression profiling and proteomic analyses. Cancer Res. 2005, 65: 10214-10222. 10.1158/0008-5472.CAN-05-0884.
29. Samuel N, Hudson TJ: Translating genomics to the clinic: implications of cancer heterogeneity. Clin Chem. 2013, 59: 127-137. 10.1373/clinchem.2012.184580.
30. Almendro V, Marusyk A, Polyak K: Cellular heterogeneity and molecular evolution in cancer. Annu Rev Pathol. 2012, 10.1146/annurev-pathol-020712-163923.
31. Julien S, Merino-Trigo A, Lacroix L, Pocard M, Goéré D, Mariani P, Landron S, Bigot L, Nemati F, Dartigues P, Weiswald LB, Lantuas D, Morgand L, Pham E, Gonin P, Dangles-Marie V, Job B, Dessen P, Bruno A, Pierré A, De Thé H, Soliman H, Nunes M, Lardier G, Calvet L, Demers B, Prévost G, Vrignaud P, Roman-Roman S, Duchamp O, Berthet C: Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer. Clin Cancer Res. 2012, 18: 5314-5328. 10.1158/1078-0432.CCR-12-0372.
32. Marusyk A, Almendro V, Polyak K: Intra-tumour heterogeneity: a looking glass for cancer?. Nat Rev Cancer. 2012, 12: 323-334.
33. Damia G, D'Incalci M: Genetic instability influences drug response in cancer cells. Curr Drug Targets. 2010, 11: 1317-1324. 10.2174/1389450111007011317.
34. Hile SE, Shabashev S, Eckert KA: Tumor-specific microsatellite instability: do distinct mechanisms underlie the MSI-L and EMAST phenotypes?. Mutat Res. 2012, 10.1016/j.mrfmmm.2012.11.003.
35. Corcos D: Unbalanced replication as a major source of genetic instability in cancer cells. Am J Blood Res. 2012, 2: 160-169.
36. Pietras A: Cancer stem cells in tumor heterogeneity. Adv Cancer Res. 2011, 112: 255-281.
37. George O, Koob GF: Individual differences in prefrontal cortex function and the transition from drug use to drug dependence. Neurosci Biobehav Rev. 2010, 35: 232-247. 10.1016/j.neubiorev.2010.05.002.
38. Gridelli C, Maione P, Colantuoni G, Rossi A: Chemotherapy of non-small cell lung cancer in elderly patients. Curr Med Chem. 2002, 9: 1487-1495. 10.2174/0929867023369565.
39. Cosset JM, Mauch PM: The role of radiotherapy for early stage Hodgkin's disease: limitations and perspectives. Ann Oncol. 1998, 9: S57-S62. 10.1093/annonc/9.suppl_5.S57.
40. Abraham I, El Sayed K, Chen ZS, Guo H: Current status on marine products with reversal effect on cancer multidrug resistance. Mar Drugs. 2012, 10: 2312-2321. 10.3390/md10102312.
41. Moncharmont C, Levy A, Gilormini M, Bertrand G, Chargari C, Alphonse G, Ardail D, Rodriguez-Lafrasse C, Magné N: Targeting a cornerstone of radiation resistance: cancer stem cell. Cancer Lett. 2012, 322: 139-147. 10.1016/j.canlet.2012.03.024.
42. Parkinson H, Sarkans U, Kolesnikov N, Abeygunawardena N, Burdett T, Dylag M, Emam I, Farne A, Hastings E, Holloway E, Kurbatova N, Lukk M, Malone J, Mani R, Pilicheva E, Rustici G, Sharma A, Williams E, Adamusiak T, Brandizi M, Sklyar N, Brazma A: ArrayExpress update - an archive of microarray and high-throughput sequencing-based functional genomics experiments. Nucleic Acids Res. 2011, 39: D1002-D1004. 10.1093/nar/gkq1040.
43. Chambers EV, Kindt AS, Semple CA: Opening sequence: computational genomics in the era of high-throughput sequencing. Genome Biol. 2011, 12: 310-10.1186/gb-2011-12-12-310.
44. Wakefield MJ: Genomics - from Neanderthals to high-throughput sequencing. Genome Biol. 2006, 7: 326-10.1186/gb-2006-7-8-326.
45. Ekmektzoglou KA, Samelis G, Karagiannis S, Zografos G, Xanthos T: Genomic instability in ulcerative colitis: a prerequisite for cancer in the inflammatory colon?. Acta Gastroenterol Belg. 2012, 75: 293-299.
46. Giaretti W, Pentenero M, Gandolfo S, Castagnola P: Chromosomal instability, aneuploidy and routine high-resolution DNA content analysis in oral cancer risk evaluation. Future Oncol. 2012, 8: 1257-1271. 10.2217/fon.12.116.
47. Sanchez-Pla A, Reverter F, Ruiz de Villa MC, Comabella M: Transcriptomics: mRNA and alternative splicing. J Neuroimmunol. 2012, 248: 23-31. 10.1016/j.jneuroim.2012.04.008.
48. Evans CO, Moreno CS, Zhan X, McCabe MT, Vertino PM, Desiderio DM, Oyesiku NM: Molecular pathogenesis of human prolactinomas identified by gene expression profiling, RT-qPCR, and proteomic analyses. Pituitary. 2008, 11: 231-245. 10.1007/s11102-007-0082-2.
49. Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, Castle J, Bartel DP, Linsley PS, Johnson JM: Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature. 2005, 433: 769-773. 10.1038/nature03315.
50. Clark TA, Sugnet CW, Ares M: Genomewide analysis of mRNA processing in yeast using splicing-specific microarrays. Science. 2002, 296: 907-910. 10.1126/science.1069415.
51. David L, Huber W, Granovskaia M, Toedling J, Palm CJ, Bofkin L, Jones T, Davis RW, Steinmetz LM: A high-resolution map of transcription in the yeast genome. Proc Natl Acad Sci U S A. 2006, 103: 5320-5325. 10.1073/pnas.0601091103.
52. Bertone P, Stolc V, Royce TE, Rozowsky JS, Urban AE, Zhu X, Rinn JL, Tongprasit W, Samanta M, Weissman S, Gerstein M, Snyder M: Global identification of human transcribed sequences with genome tiling arrays. Science. 2004, 306: 2242-2246. 10.1126/science.1103388.
53. Roepman P, Wessels LF, Kettelarij N, Kemmeren P, Miles AJ, Lijnzaad P, Tilanus MG, Koole R, Hordijk GJ, van der Vliet PC, Reinders MJ, Slootweg PJ, Holstege FC: An expression profile for diagnosis of lymph node metastases from primary head and neck squamous cell carcinomas. Nat Genet. 2005, 37: 182-186. 10.1038/ng1502.
54. Borgan E, Sitter B, Lingjærde OC, Johnsen H, Lundgren S, Bathen TF, Sørlie T, Børresen-Dale AL, Gribbestad IS: Merging transcriptomics and metabolomics - advances in breast cancer profiling. BMC Cancer. 2010, 10: 628-10.1186/1471-2407-10-628.
55. Okoniewski MJ, Miller CJ: Hybridization interactions between probesets in short oligo microarrays lead to spurious correlations. BMC Bioinforma. 2006, 7: 276-10.1186/1471-2105-7-276.
56. Royce TE, Rozowsky JS, Gerstein MB: Toward a universal microarray: prediction of gene expression through nearest-neighbor probe sequence identification. Nucleic Acids Res. 2007, 35: e99-10.1093/nar/gkm549.
57. Zhan X, Desiderio DM: Comparative proteomics analysis of human pituitary adenomas: current status and future perspective. Mass Spectrom Rev. 2005, 24: 783-813. 10.1002/mas.20039.
58. Sabidó E, Selevsek N, Aebersold R: Mass spectrometry-based proteomics for systems biology. Curr Opin Biotechnol. 2012, 23: 591-597. 10.1016/j.copbio.2011.11.014.
59. Bensimon A, Heck AJ, Aebersold R: Mass spectrometry-based proteomics and network biology. Annu Rev Biochem. 2012, 81: 379-405. 10.1146/annurev-biochem-072909-100424.
60. Aebersold R, Mann M: Mass spectrometry-based proteomics. Nature. 2003, 422: 198-207. 10.1038/nature01511.
61. Zhan X, Desiderio DM: Heterogeneity analysis of the human pituitary proteome. Clin Chem. 2003, 49: 1740-1751. 10.1373/49.10.1740.
62. Desiderio DM, Zhan X: A study of the human pituitary proteome: the characterization of differentially expressed proteins in an adenoma compared to a control. Cell Mol Biology. 2003, 49: 689-712.
63. Liu J, Zhan X, Li M, Li G, Zhang P, Xiao Z, Shao M, Peng F, Hu R, Chen Z: Mitochondrial proteomics of nasopharyngeal carcinoma metastasis. BMC Med Genomics. 2012, 5: 62-10.1186/1755-8794-5-62.
64. Zhou G, Li H, DeCamp D, Chen S, Shu H, Gong Y, Flaig M, Gillespie JW, Hu N, Taylor PR, Emmert-Buck MR, Liotta LA, Petricoin EF, Zhao Y: 2D differential in-gel electrophoresis for the identification of esophageal scans cell cancer-specific protein markers. Mol Cell Proteomics. 2002, 1: 117-124. 10.1074/mcp.M100015-MCP200.
65. Shiio Y, Aebersold R: Quantitative proteome analysis using isotope-coded affinity tags and mass spectrometry. Nat Protoc. 2006, 1: 139-145. 10.1038/nprot.2006.22.
66. Schrimpf SP, Meskenaite V, Brunner E, Rutishauser D, Walther P, Eng J, Aebersold R, Sonderegger P: Proteomic analysis of synaptosomes using isotope-coded affinity tags and mass spectrometry. Proteomics. 2005, 5: 2531-2541. 10.1002/pmic.200401198.
67. Munday DC, Surtees R, Emmott E, Dove BK, Digard P, Barr JN, Whitehouse A, Matthews D, Hiscox JA: Using SILAC and quantitative proteomics to investigate the interactions between viral and host proteomes. Proteomics. 2012, 12: 666-672. 10.1002/pmic.201100488.
68. Rao KC, Palamalai V, Dunlevy JR, Miyagi M: Peptidyl-Lys metalloendopeptidase-catalyzed 18O labeling for comparative proteomics: application to cytokine/lipolysaccharide-treated human retinal pigment epithelium cell line. Mol Cell Proteomics. 2005, 4: 1550-1557. 10.1074/mcp.M500150-MCP200.
69. Miyagi M, Rao KC: Proteolytic 18O-labeling strategies for quantitative proteomics. Mass Spectrom Rev. 2007, 26: 121-136. 10.1002/mas.20116.
70. Chaerkady R, Pandey A: Applications of proteomics to lab diagnosis. Annu Rev Pathol. 2008, 3: 485-498. 10.1146/annurev.pathmechdis.3.121806.151419.
71. Chen X, Sun L, Yu Y, Xue Y, Yang P: Amino acid-coded tagging approaches in quantitative proteomics. Expert Rev Proteomics. 2007, 4: 25-37. 10.1586/14789450.4.1.25.
72. Lee JY, Pajarillo EA, Kim MJ, Chae JP, Kang DK: Proteomic and transcriptional analysis of Lactobacillus johnsonii PF01 during bile salt exposure by iTRAQ shotgun proteomics and quantitative RT-PCR. J Proteome Res. 2013, 12: 432-443. 10.1021/pr300794y.
73. Jankova L, Chan C, Fung CL, Song X, Kwun SY, Cowley MJ, Kaplan W, Dent OF, Bokey EL, Chapuis PH, Baker MS, Robertson GR, Clarke SJ, Molloy MP: Proteomic comparison of colorectal tumours and non-neoplastic mucosa from paired patient samples using iTRAQ mass spectrometry. Mol Biosyst. 2011, 7: 2997-3005. 10.1039/c1mb05236e.
74. Zhang B, VerBerkmoes NC, Langston MA, Uberbacher E, Hettich RL, Samatova NF: Detecting differential and correlated protein expression in label-free shotgun proteomics. J Proteome Res. 2006, 5: 2909-2918. 10.1021/pr0600273.
75. Gao BB, Stuart L, Feener EP: Label-free quantitative analysis of one-dimensional PAGE LC/MS/MS proteome: application on angiotensin II-stimulated smooth muscle cells secretome. Mol Cell Proteomics. 2008, 7: 2399-2409. 10.1074/mcp.M800104-MCP200.
76. Rabilloud T: Two-dimensional gel electrophoresis in proteomics: old, old fashioned, but it still climbs up the mountains. Proteomics. 2002, 2: 3-10. 10.1002/1615-9861(200201)2:1<3::AID-PROT3>3.0.CO;2-R.
77. Cravatt BF, Simon GM, Yates JR: The biological impact of mass-spectrometry-based proteomics. Nature. 2007, 450: 991-1000. 10.1038/nature06525.
78. Domon B, Aebersold R: Mass spectrometry and protein analysis. Science. 2006, 312: 212-217. 10.1126/science.1124619.
79. Scigelova M, Makarov A: Orbitrap mass analyzer - overview and applications in proteomics. Proteomics. 2006, 6 (Suppl 2): 16-21.
80. Schmidt A, Gehlenborg N, Bodenmiller B, Mueller LN, Campbell D, Mueller M, Aebersold R, Domon B: An integrated, directed mass spectrometric approach for in-depth characterization of complex peptide mixtures. Mol Cell Proteomics. 2008, 7: 2138-2150. 10.1074/mcp.M700498-MCP200.
81. Zhan X, Desiderio DM: A reference map of a human pituitary adenoma proteome. Proteomics. 2003, 3: 699-713. 10.1002/pmic.200300408.
82. Zhan X, Evans CO, Oyesiku NM, Desiderio DM: Proteomics and transcriptomics analyses of secretagogin down-regulation in human non-functional pituitary adenomas. Pituitary. 2003, 6: 189-202.
83. Zhan X, Giorgianni F, Desiderio DM: Proteomics analysis of growth hormone isoforms in the human pituitary. Proteomics. 2005, 5: 1228-1241. 10.1002/pmic.200400987.
84. Zeng GQ, Zhang PF, Deng X, Yu FL, Li C, Xu Y, Yi H, Li MY, Hu R, Zuo JH, Li XH, Wan XX, Qu JQ, He QY, Li JH, Ye X, Chen Y, Li JY, Xiao ZQ: Identification of candidate biomarkers for early detection of human lung squamous cell cancer by quantitative proteomics. Mol Cell Proteomics. 2012, 11: M111 013946-
85. Marzinke MA, Choi CH, Chen L, Shih IM, Chan DW, Zhang H: Proteomic analysis of temporally stimulated ovarian cancer cells for biomarker discovery. Mol Cell Proteomics. 2012, 10.1074/mcp.M112.019521.
86. Franceschini A, Szklarczyk D, Frankild S, Kuhn M, Simonovic M, Roth A, Lin J, Minguez P, Bork P, von Mering C, Jensen LJ: STRING v9.1: protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Res. 2012, 10.1093/nar/gks1094.
87. De Las RJ, Prieto C: Protein interactions: mapping interactome networks to support drug target discovery and selection. Methods Mol Biol. 2012, 910: 279-296. 10.1007/978-1-61779-965-5_12.
88. Schmidt C: Metabolomics takes its place as latest up-and-coming "omic" science. J Natl Cancer Inst. 2004, 96: 732-734. 10.1093/jnci/96.10.732.
89. Vadigepalli R, Chakravarthula P, Zak DE, Schwaber JS, Gonye GE: PAINT: a promoter analysis and interaction network generation tool for gene regulatory network identification. OMICS. 2003, 7: 235-252. 10.1089/153623103322452378.
90. Pommier Y, Sordet O, Antony S, Hayward RL, Kohn KW: Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. Oncogene. 2004, 23: 2934-2949. 10.1038/sj.onc.1207515.
91. Chen R, Snyder M: Promise of personalized omics to precision medicine. Wiley Interdiscip Rev Syst Biol Med. 2013, 5: 73-82. 10.1002/wsbm.1198.
92. Ginsburg GS, Kuderer NM: Comparative effectiveness research, genomics-enabled personalized medicine, and rapid learning health care: a common bond. J Clin Oncol. 2012, 30: 4233-4242. 10.1200/JCO.2012.42.6114.
93. Qattan M, Demonacos C, Krstic-Demonacos M: Roadmap to personalized medicine. Croat Med J. 2012, 53: 294-297. 10.3325/cmj.2012.53.294.
94. Hood L: Systems biology: integrating technology, biology, and computation. Mech Ageing Dev. 2003, 124: 9-16. 10.1016/S0047-6374(02)00164-1.
95. Aderem A: Systems biology: its practice and challenges. Cell. 2005, 121: 511-513. 10.1016/j.cell.2005.04.020.
96. Hood L, Tian Q: Systems approaches to biology and disease enable translational systems medicine. Genomics Proteomics Bioinformatics. 2012, 10: 181-185. 10.1016/j.gpb.2012.08.004.
97. Cortazar P, Johnson BE: Review of the efficacy of individualized chemotherapy selected by invitro drug sensitivity testing for patients with cancer. J Clin Oncol. 1999, 17: 1625-1631.
98. Blackwell KL, Burstein HJ, Storniolo AM, Rugo H, Sledge G, Koehler M, Ellis C, Casey M, Vukelja S, Bischoff J, Baselga J, O'Shaughnessy J: Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol. 2010, 28: 1124-1130. 10.1200/JCO.2008.21.4437.